VA106483 Dose Response Study in Elderly Males

Vantia Ltd10 enrolled

Overview

The main purpose of the study is to evaluate the way VA106483 enters and leaves the blood and tissues over time and how the drug acts on and in the body at various dose levels compared to placebo in the same volunteer.

VA106483 is intended to be used as a treatment for patients suffering from nocturia (defined as waking to urinate at least once per night between periods of sleep). Nocturia is a condition that often worsens as sufferers get older. This may be due to an over-active bladder muscle, the bladder being able to hold less urine at night-time or over production of urine in the bladder at night. The only antidiuretic approved for the treatment (in some countries) of nocturia is the peptide drug, desmopressin. However, as it can cause hyponatraemia in a proportion of patients above the age of 65 years it is contra-indicated in the elderly. This side-effect has not been observed with VA106483, making it potentially suitable for treating the elderly. The purpose of this study is to confirm that duration of action of VA106483 can be effectively controlled by dose and therefore that satisfactory clinical outcome in the treatment of nocturia can be achieved by individual dose titration. Subjects will be water-loaded, dosed with either VA106483 or placebo and then urine production will be monitored to assess any anti-diuretic effect.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Nocturia

Interventions

VA106483DRUG

Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7

PlaceboDRUG

Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7

Eligibility

Sex: MALEMin age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Male, Age: 65 years and above * Using adequate contraception * Medical history without clinically significant pathologies; no evidence of serious pathology or disease * Physical examination parameters without signs of serious disease * No clinically significant ECG and lab safety tests (sodium must be within normal range) * Willing and able to participate and provides written informed consent Exclusion Criteria: * Cardiac insufficiency; signs or symptoms suggestive of heart failure or requiring treatment with diuretics * Supine arterial blood pressure higher than 170/100 mmHg or less than 105/60 mm Hg * Presence of poorly controlled endocrine disorders * Renal insufficiency, active hepatic and/or biliary disease * Hyponatraemia. Serum sodium level must be within normal limits * Syndrome of inappropriate antidiuretic hormone (ADH) secretion * Symptoms suggestive of psychogenic or habitual polydipsia or of diabetes insipidus * Known hypersensitivity to the IP or any constituent of the IP * Use of any non-prescription preparation within 72 hours prior to study entry, with the exception of defined pain killers * A history of alcohol abuse or drug addiction within the last 2 years * Positive screen for HIV, hepatitis B or C * Currently taking any diuretics or any concomitant medication known to be a cytochrome 3A4 inhibitor * Other protocol defined eligibility criteria may apply.

Locations (1)

Quintiles Phase I Services

Overland Park, Kansas, United States

Outcomes

Primary Outcomes

Urine volume and osmolality and plasma PK assessments

Time frame: 24 Hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.